|1.||Wurz, Gregory T: 11 articles (11/2014 - 07/2002)|
|2.||DeGregorio, Michael W: 10 articles (11/2014 - 07/2002)|
|3.||Ospemifene Study Group: 5 articles (04/2014 - 05/2010)|
|4.||Komm, Barry S: 4 articles (09/2015 - 03/2015)|
|5.||Lammintausta, Risto: 4 articles (11/2013 - 09/2003)|
|6.||Pickar, James H: 3 articles (09/2015 - 03/2015)|
|7.||Taylor, Hugh S: 3 articles (07/2015 - 05/2009)|
|8.||Archer, David F: 3 articles (07/2015 - 01/2015)|
|9.||Kangas, L: 3 articles (05/2014 - 06/2007)|
|10.||Bachmann, Gloria A: 3 articles (06/2013 - 05/2010)|
05/01/2010 - "Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study."
04/01/2015 - "Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial."
06/01/2014 - "Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial."
04/01/2013 - "One-year long-term safety extension study of ospemifene for the treatment of vulvar and vaginal atrophy in postmenopausal women with a uterus."
01/01/2012 - "Ospemifene, a new drug indicated for the treatment of vulvovaginal atrophy, has completed phase III clinical trials. "
01/01/2014 - "Results of Phase III clinical trials showed that ospemifene significantly improved the vaginal maturation index (decreased parabasal cells and increased superficial cells), decreased vaginal pH, and decreased severity of the self-identified most bothersome symptom (dyspareunia or vaginal dryness) compared to placebo. "
06/01/2013 - "Analysis of the intent-to-treat (n = 605) population found the efficacy of ospemifene to be significantly greater than that of placebo for each of the following coprimary endpoints: percentages of parabasal and superficial cells, vaginal pH, and severity of dyspareunia. "
10/01/2014 - "Several studies have evaluated the effects of ospemifene on VVA and dyspareunia and indicate an improvement in subjective findings. "
12/01/2015 - "This is a comprehensive review describing the clinical safety and efficacy of ospemifene for the treatment of dyspareunia and VVA. "
10/01/2014 - "In this review, current evidence for the safety and efficacy of ospemifene in the treatment of moderate-to-severe VVA and dyspareunia are evaluated. "
|3.||Breast Neoplasms (Breast Cancer)
12/01/2015 - "Further clinical studies are needed to evaluate the preclinical and early clinical findings of antagonistic to neutral effect on breast tissue and positive effect on bone, which, in the future, may support the use of ospemifene to prevent bone loss or treat VVA in women at high risk or with breast cancer."
01/01/2012 - "In this study, we test the effects of three dosing levels of ospemifene in both the prevention and treatment of breast cancer in the MTag.Tg"
10/30/2014 - "The synthesis of some novel Ospemifene derived analogs and their evaluation as anti-breast cancer agents against MCF-7 (ER-positive) and MDA-MB-231 (ER-negative) human breast cancer cell lines are described. "
10/30/2014 - "Design, synthesis and evaluation of Ospemifene analogs as anti-breast cancer agents."
03/01/2013 - "Additional research addressing the expanded use of ospemifene in breast cancer patients is also warranted. "
09/01/2003 - "Such effects would be advantageous if ospemifene were found to be effective in the long-term prevention of osteoporosis."
01/01/2013 - "Ospemifene warrants further clinical investigation for the treatment and prevention of osteoporosis and breast cancer. "
09/01/2003 - "Ospemifene, a novel selective estrogen receptor modulator, shows a potential for prevention and treatment of osteoporosis in postmenopausal women. "
06/01/2001 - "Ospemifene (FC-1271a) is a novel selective estrogen receptor modulator under development for osteoporosis prevention. "
11/01/2005 - "The results of these two studies suggest that women taking ospemifene for osteoporosis and/or urogenital atrophy may further benefit from ospemifene's breast cancer chemopreventive effects."
12/11/2013 - "In contrast, ospemifene has an estrogenic effect on bone, as seen by improved bone mineral density, strength, mass, and histomorphometry in preclinical models, consistent with improvements in markers of bone resorption and formation in postmenopausal women. "
03/01/2004 - "Ospemifene decreased bone resorption dose-dependently, as seen from falls in NTX by 6.1, 9.4 and 12.9% in the 30, 60 and 90 mg ospemifene groups, respectively (p < 0.05 for all dose levels when compared to placebo). "
06/01/2007 - "Tamoxifen had an oestrogen receptor dependent, direct, inhibitory effect on human osteoclast differentiation and bone resorption, whereas ospemifene and raloxifene required osteoblastic cells to achieve a similar inhibition. "
06/01/2007 - "In CD14+ monocyte cultures, tamoxifen directly inhibited human osteoclast formation and bone resorption, while raloxifene and ospemifene had no inhibitory effect. "
01/01/2014 - "Further, histomorphometric measures revealed decreased bone resorption after 4 weeks of ospemifene treatment, with effects similar to other SERMs (raloxifene and droloxifene). "
|1.||Selective Estrogen Receptor Modulators (SERM)
|4.||tartrate salt cis- 1R- (4'- pyrrolidinoethoxyphenyl)- 2S- phenyl- 6- hydroxy- 1,2,3,4- tetrahydronaphthalene (Lasofoxifene)
|9.||LY 353381 (LY353381)
|2.||Heterologous Transplantation (Xenotransplantation)